CL2008002539A1 - Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral - Google Patents

Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral

Info

Publication number
CL2008002539A1
CL2008002539A1 CL2008002539A CL2008002539A CL2008002539A1 CL 2008002539 A1 CL2008002539 A1 CL 2008002539A1 CL 2008002539 A CL2008002539 A CL 2008002539A CL 2008002539 A CL2008002539 A CL 2008002539A CL 2008002539 A1 CL2008002539 A1 CL 2008002539A1
Authority
CL
Chile
Prior art keywords
treatment
pharmaceutical composition
viral infection
substituted indole
derivative compounds
Prior art date
Application number
CL2008002539A
Other languages
English (en)
Inventor
Frank Bennett
Mousumi Sannigrahi
Gopinadhan N Anilkumar
Francisco Velazquez
Kevin X Chen
Tin-Yau Chan
Venk
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39968138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008002539(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of CL2008002539A1 publication Critical patent/CL2008002539A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Compuestos derivados de indol-2-carboxi sustituido; composición farmacéutica; y uso en el tratamiento de una infección viral.
CL2008002539A 2007-08-29 2008-08-28 Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral CL2008002539A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96869807P 2007-08-29 2007-08-29

Publications (1)

Publication Number Publication Date
CL2008002539A1 true CL2008002539A1 (es) 2009-07-17

Family

ID=39968138

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002539A CL2008002539A1 (es) 2007-08-29 2008-08-28 Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral

Country Status (17)

Country Link
US (1) US8614229B2 (es)
EP (1) EP2408761B1 (es)
JP (2) JP5272008B2 (es)
KR (1) KR20100067652A (es)
CN (1) CN101821252A (es)
AR (1) AR068106A1 (es)
AU (1) AU2008295484B2 (es)
BR (1) BRPI0815811A2 (es)
CA (1) CA2697454C (es)
CL (1) CL2008002539A1 (es)
EC (1) ECSP10010004A (es)
ES (1) ES2447543T3 (es)
MX (1) MX2010002317A (es)
PE (1) PE20090630A1 (es)
RU (1) RU2010111551A (es)
TW (1) TW200924780A (es)
WO (1) WO2009032124A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
CA2673249C (en) 2006-12-22 2013-04-30 Schering Corporation 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections
CN101611025A (zh) 2006-12-22 2009-12-23 先灵公司 5,6-环化的吲哚衍生物及其使用方法
US8546420B2 (en) 2006-12-22 2013-10-01 Merck Sharp & Dohme Corp. 4, 5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
JP5258889B2 (ja) * 2007-08-29 2013-08-07 メルク・シャープ・アンド・ドーム・コーポレーション ウイルス感染症の治療のための２，３−置換アザインドール誘導体
RU2010111551A (ru) 2007-08-29 2011-10-10 Шеринг Корпорейшн (US) Замещенные индольные производные и способы их применения
EP2222672B1 (en) * 2007-11-16 2013-12-18 Merck Sharp & Dohme Corp. 3-aminosulfonyl substituted indole derivatives and methods of use thereof
WO2009064848A1 (en) * 2007-11-16 2009-05-22 Schering Corporation 3-heterocyclic substituted indole derivatives and methods of use thereof
WO2009152200A1 (en) * 2008-06-13 2009-12-17 Schering Corporation Tricyclic indole derivatives and methods of use thereof
AU2010253791A1 (en) 2009-05-29 2011-11-24 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C
WO2011049988A2 (en) * 2009-10-20 2011-04-28 Eiger Biopharmaceuticals, Inc. Indazoles to treat flaviviridae virus infection
MX2012005706A (es) 2009-11-21 2012-06-12 Hoffmann La Roche Compuestos antivirales heterociclicos.
CA2782024A1 (en) 2009-11-25 2011-06-03 Schering Corporation Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
PE20130062A1 (es) 2010-03-09 2013-02-28 Merck Sharp & Dohme Compuestos de sililo triciclicos fusionados para el tratamiento de enfermedades virales
MX2012014235A (es) * 2010-07-07 2013-01-28 Hoffmann La Roche Compuestos hetericiclicos antiviricos.
EP2598149A4 (en) 2010-07-26 2014-09-10 Merck Sharp & Dohme SUBSTITUTED BIPHENYLENE COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF VIRUS DISEASES
EP2621279B1 (en) 2010-09-29 2018-04-04 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
EA025151B1 (ru) 2010-10-26 2016-11-30 Пресидио Фармасьютикалс, Инк. Ингибиторы вируса гепатита с
US9090593B2 (en) 2010-12-09 2015-07-28 Amgen Inc. Bicyclic compounds as Pim inhibitors
EP2688886A1 (en) 2011-03-22 2014-01-29 Amgen Inc. Azole compounds as pim inhibitors
SG194485A1 (en) 2011-04-13 2013-12-30 Merck Sharp & Dohme 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2012142075A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
EP2755981A4 (en) 2011-09-14 2015-03-25 Merck Sharp & Dohme HETEROCYCLIC COMPOUNDS CONTAINING SILYL AND METHODS OF USING THE SAME FOR TREATING VIRAL DISEASES
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
AR092959A1 (es) 2012-10-17 2015-05-06 Merck Sharp & Dohme Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
US9457039B2 (en) 2012-10-17 2016-10-04 Merck Sharp & Dohme Corp. 2′-disubstituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2014059901A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. 2'-cyano substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
KR20150086325A (ko) 2012-11-19 2015-07-27 머크 샤프 앤드 돔 코포레이션 바이러스성 질환을 치료하기 위한 2''-알키닐 치환된 뉴클레오시드 유도체
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9765107B2 (en) 2013-06-18 2017-09-19 Merck Sharp & Dohme Corp. Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2014205592A1 (en) 2013-06-24 2014-12-31 Merck Sharp & Dohme Corp. Heterocyclic compounds and methods of use thereof for treatment of hepatitis c
WO2014205593A1 (en) 2013-06-24 2014-12-31 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for treatment of viral diseases
EP3063140A4 (en) 2013-10-30 2017-11-08 Merck Sharp & Dohme Corp. Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof
CR20170568A (es) 2015-06-26 2018-04-20 Takeda Pharmaceuticals Co Compuesto heterocíclico
WO2017069173A1 (ja) 2015-10-20 2017-04-27 武田薬品工業株式会社 複素環化合物
US10899788B2 (en) 2016-06-20 2021-01-26 Merck Sharp & Dohme Corp. Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases
US20220281824A1 (en) * 2019-07-30 2022-09-08 Oregon State University Aryl hydrocarbon receptor activators

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE648639C (de) 1935-05-19 1937-08-05 I G Farbenindustrie Akt Ges Verfahren zur Darstellung von Dipyrrolen
US3632805A (en) * 1967-12-08 1972-01-04 Sumitomo Chemical Co Process for producing 1-aminoalkyl-benzodiazepine derivatives
DE2002208C3 (de) * 1969-01-25 1978-04-13 Sumitomo Chemical Co., Ltd., Osaka (Japan) 1 (Dialkylaminoacyl)-5-phenyl-7chlor-2,3-dihydro- IH-1,4-benzodiazepinderivate
JPS4945876B1 (es) 1970-01-29 1974-12-06
US3867372A (en) * 1970-02-03 1975-02-18 Sumitomo Chemical Co Benzodiazepine process
DE2166504B2 (de) * 1970-08-31 1980-01-17 Sumitomo Chemical Co., Ltd., Osaka (Japan) 1 -Alkoxyalkoxyalkyl^-halogen-Sphenyl-13-dihydro-2H-l,4-benzodiazepin-2-one und ihre Salze sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
JPS4843359B1 (es) * 1970-08-31 1973-12-18
JPS494461B1 (es) 1970-12-17 1974-02-01
AU575854B2 (en) 1983-10-04 1988-08-11 Shionogi & Co., Ltd. 7beta-(carboxyalkenamido) cephalosporins
NZ220764A (en) * 1986-07-02 1989-09-27 Shionogi & Co Crystalline form of 7beta((z)-2-(2-aminothiazol-4-yl)-4- carboxybut-2-enoylamino)-3-cephem-4-carboxylic acid and pharmaceutical compositions
US5017380A (en) 1986-07-02 1991-05-21 Shionogi & Co., Ltd. Gelatin hard capsule containing crystalline hydrate of oral cephalosporin
CA2038925A1 (en) 1990-03-26 1991-09-27 Takashi Sohda Indole derivatives, their production and use
JPH04149429A (ja) 1990-10-12 1992-05-22 Fuji Photo Film Co Ltd ハロゲン化銀カラー反転写真感光材料およびそれを用いた画像形成方法
IT1278077B1 (it) 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
KR100509388B1 (ko) 1996-10-18 2005-08-23 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 간염 ｃ 바이러스 ｎｓ３ 프로테아제의 저해제
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
WO1999007734A2 (en) 1997-08-11 1999-02-18 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
FR2768146B1 (fr) 1997-09-05 2000-05-05 Oreal Nouveaux composes de la famille des indole-carboxyliques et leur utilisation
BR0109861A (pt) * 2000-04-05 2003-06-10 Schering Corp Inibidores macrocìclicos de protease ns3-serina do vìrus da hepatite c compreendendo porções n-cìclicas p2
WO2001074420A1 (fr) 2000-04-05 2001-10-11 Toray Industries, Inc. Adsorbants pour proteines de la famille hmg et colonne de purification de liquide organique
AR030558A1 (es) 2000-04-19 2003-08-27 Schering Corp COMPUESTOS MACROCICLICOS, QUE INCLUYEN ENANTIOMEROS, ESTEROISOMEROS, ROTAMEROS Y TAUTOMEROS, SALES Y SOLVATOS FARMACEUTICAMENTE ACEPTABLES, COMPOSICIoN FARMACEUTICA, UN METODO PARA SU PREPARACION Y EL USO DE DICHOS COMPUESTOS PARA LA ELABORACION DE UN MEDICAMENTO, INHIBIDORES DE LA SERINA PROTEASA,
CA2410682A1 (en) 2000-07-21 2002-01-31 Schering Corporation Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
CN102372764A (zh) * 2000-07-21 2012-03-14 先灵公司 用作丙型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的新型肽
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
MXPA03003174A (es) 2000-10-10 2003-07-14 Smithkline Beecham Corp Indoles substituidos, composiciones farmaceuticas que contienen dichos indoles y su uso como agentes de enlace ppar-y..
JP4368581B2 (ja) 2000-12-12 2009-11-18 シェーリング コーポレイション Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としてのジアリールペプチド
JP2004518658A (ja) * 2000-12-18 2004-06-24 イーライ・リリー・アンド・カンパニー 新規なｓＰＬＡ２インヒビター
WO2002068412A1 (en) 2001-02-22 2002-09-06 School Of Pharmacy, University Of London Pyrrolo-indole and pyrrolo-quinoline derivatives as prodrugs for tumour treatment
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
FR2839718B1 (fr) * 2002-05-17 2004-06-25 Sanofi Synthelabo Derives d'indole, leur procede de preparation et les compositions pharmaceutiques en contenant
EP1554271A1 (en) 2002-10-15 2005-07-20 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
JP2004149429A (ja) 2002-10-29 2004-05-27 Takeda Chem Ind Ltd インドール化合物およびその用途
US20050075331A1 (en) * 2003-10-06 2005-04-07 Pratt John K. Anti-infective agents
NZ543897A (en) 2003-05-30 2009-04-30 Gemin X Pharmaceuticals Canada Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
GB0323845D0 (en) * 2003-10-10 2003-11-12 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
WO2005047324A2 (en) * 2003-11-10 2005-05-26 Schering Corp ANTI-INTERLEUKIN ANTIBODY-10
SG186041A1 (en) 2004-02-27 2012-12-28 Merck Sharp & Dohme Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
BRPI0508079A (pt) 2004-03-01 2007-07-17 Viropharma Inc composto ou uma forma cristalina ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos de tratar ou prevenir uma infecção viral com hepatite c em um mamìfero e de inibir replicação de um vìrus da hepatite c
WO2005107745A1 (en) * 2004-05-06 2005-11-17 Schering Corporation An inhibitor of hepatitis c
EP1604988A1 (en) 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
WO2007084413A2 (en) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
CN101035528A (zh) 2004-09-23 2007-09-12 惠氏公司 治疗丙型肝炎病毒感染的咔唑和环戊二烯并吲哚衍生物
DE102004047272A1 (de) 2004-09-24 2006-04-06 Schering Ag Inhibitoren der löslichen Adenylatzyklase
KR20070068427A (ko) 2004-10-26 2007-06-29 이스티투토 디 리세르쉐 디 비올로지아 몰레콜라레 피. 안젤레티에스.피.에이. 항바이러스제로서의 테트라사이클릭 인돌 유도체
JP4149429B2 (ja) 2004-10-26 2008-09-10 本田技研工業株式会社 車両の走行安全装置
CA2593450A1 (en) 2005-01-14 2006-07-20 Genelabs Technologies, Inc. Indole derivatives for treating viral infections
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
CN101309925A (zh) 2005-09-23 2008-11-19 先灵公司 作为治疗药物的稠合四环类代谢型谷氨酸受体1拮抗剂
WO2007084435A2 (en) 2006-01-13 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
PE20080197A1 (es) 2006-02-09 2008-04-11 Schering Corp Combinaciones que involucran el (los) inhibidor (es) de la proteasa del hcv, y metodos de tratamiento relacionado al (los) mismos(s)
US8546420B2 (en) * 2006-12-22 2013-10-01 Merck Sharp & Dohme Corp. 4, 5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
CA2673249C (en) * 2006-12-22 2013-04-30 Schering Corporation 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections
CN101611025A (zh) * 2006-12-22 2009-12-23 先灵公司 5,6-环化的吲哚衍生物及其使用方法
RU2010111551A (ru) 2007-08-29 2011-10-10 Шеринг Корпорейшн (US) Замещенные индольные производные и способы их применения
JP5258889B2 (ja) * 2007-08-29 2013-08-07 メルク・シャープ・アンド・ドーム・コーポレーション ウイルス感染症の治療のための２，３−置換アザインドール誘導体
JP5272007B2 (ja) * 2007-08-29 2013-08-28 メルク・シャープ・アンド・ドーム・コーポレーション ウイルス感染症を治療するための２，３−置換インドール誘導体
JP4737166B2 (ja) 2007-09-07 2011-07-27 株式会社デンソー 目詰まり検出装置
WO2009064848A1 (en) * 2007-11-16 2009-05-22 Schering Corporation 3-heterocyclic substituted indole derivatives and methods of use thereof
EP2222672B1 (en) * 2007-11-16 2013-12-18 Merck Sharp & Dohme Corp. 3-aminosulfonyl substituted indole derivatives and methods of use thereof

Also Published As

Publication number Publication date
BRPI0815811A2 (pt) 2015-02-18
MX2010002317A (es) 2010-03-22
EP2408761A1 (en) 2012-01-25
US8614229B2 (en) 2013-12-24
KR20100067652A (ko) 2010-06-21
JP2013100375A (ja) 2013-05-23
CN101821252A (zh) 2010-09-01
PE20090630A1 (es) 2009-05-16
AU2008295484B2 (en) 2013-09-26
TW200924780A (en) 2009-06-16
US20110104110A1 (en) 2011-05-05
CA2697454C (en) 2015-11-03
EP2408761B1 (en) 2014-01-01
ES2447543T3 (es) 2014-03-12
AU2008295484A1 (en) 2009-03-12
JP2010537981A (ja) 2010-12-09
AR068106A1 (es) 2009-11-04
CA2697454A1 (en) 2009-03-12
WO2009032124A1 (en) 2009-03-12
RU2010111551A (ru) 2011-10-10
ECSP10010004A (es) 2010-03-31
JP5272008B2 (ja) 2013-08-28

Similar Documents

Publication Publication Date Title
CL2008002539A1 (es) Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral
CL2008002538A1 (es) Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral
CL2012000573A1 (es) Compuestos derivados de bifenil-pirrolidinil-imidazol; composicion farmaceutica que los comprende; su uso en el tratamiento de una infeccion viral por hcv.
CL2007003686A1 (es) Compuestos derivados de indol con anillo unido en las posiciones 4,5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para tratar una infeccion viral.
CL2008002540A1 (es) Compuestos derivados aza-indol-2,3-sustituidos; composicion farmaceutica; y uso ene l tratamiento de una infeccion viral.
DOP2011000203A (es) Derivados de pirimidin indol para el tratamiento de cancer
CL2007002167A1 (es) Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
CL2008003690A1 (es) Compuestos derivados de amonobenzamida; composicion farmceutica que comprende los compuestos; y uso para controlar parasitos.
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
CL2011001224A1 (es) Compuestos derivados de benzofurano-3-carboxamida; composicion farmaceutica que los comprende; y su uso en tratamiento del virus de la hepatitis c.
CL2008003406A1 (es) Compuestos derivados de quinolina; composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vih.
ECSP077412A (es) Derivados de indol tetracíclicos como agentes antivíricos
CR11819A (es) Compuestos de isoindolina 5-sustituidos
NI200900040A (es) Derivados de quinazolinona 5-substituidos como agentes antitumorales.
ECSP099663A (es) Derivados y composiciones que comprenden isoindolina 4'-o-sustituida y métodos para utilizar la misma
CL2009001346A1 (es) Compuestos derivados heterociclicos, inhibidores de la adn girasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion bacteriana.
CL2010001426A1 (es) Compuestos derivados de triciclos, inhibidores de la proteina quinasa; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades oncologicas e inmunologicas.
NI201000041A (es) Derivados y composiciones que comprenden quinazolinona 6-, 7-, u 8 - sustituida y métodos para utilizar la misma.
CL2008002049A1 (es) Compuestos derivados de aminoindol macrociclicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CL2008002893A1 (es) Compuestos derivados de n-fenil-(piridin-3-il) acetamida sustituidas; composicion farmaceutica; procedimiento de preparacion; y su uso para prevenir o tratar el cancer.
CL2010001634A1 (es) Compuestos derivados de nucleosidos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que los comprende; y combinacion farmaceutica.
CL2010000804A1 (es) Compuestos derivados de 3-(1 h-pirrol-2-il-metil)-1 ,3-dihidro-2h-indol-2-ona; procedimientos de preparación de dichos compuestos; composición farmacéutica y combinación farmacéutica que los comprende; y su uso para el tratamiento de cáncer.
UY31273A1 (es) Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53